Review
Year 2017,
Volume: 9 Issue: 2, 32 - 38, 15.03.2017
Abstract
Abstract
Asthma is a chronic inflammatory airway disease that affecting 1-18% of the world's population. The wheeze is characterized by shortness of breath, a feeling of tightness in the chest or cough and expiratory airway limitation with variable clinical presentation. Symptoms and limitation of airway can be corrected by spontaneous or medical treatment. We summarize the updated treatment of asthma in the context of literature.
References
- Kaynaklar 1.Global strategy for asthma management and prevention. GINAreport 2016. http://www.ginasthma.org/2.Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med2004;10:44-50. 3.Anderson GP. Endotyping asthma: new insights into key pat-hogenic mechanisms in a complex, heterogeneous disease. Lan-cet 2008;372:1107-19. 4.British guideline on the Management of Asthma2014.https://www.brit-thoracic.org.uk/ 5.Archibald MM, Scott SD. The information needs of North Ame-rican parents of children with asthma: a state-of-the-sciencereview of the literature. J Pediatr Health Care. 2014 Jan-Feb;28(1):5-13.e2 6.Asthma Action Plan. Asthma Foundation NSW 2012. Retrie-ved from http://www.asthmafoundation.org.au/asthma acti-onplan.aspx 7.Gotzsche PC, Johansen HK. House dust mite control measu-res for asthma. Cochrane Database Syst Rev. 2008. 8.Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med1995;333(8):499-506. 9.McDonald N, Bara A, McKean MC. Anticholinergic therapyfor chronic asthma in children over two years of age. Coch-rane Database Syst Rev 2003;(3). 10.Castro-Rodriguez JA, Rodrigo GJ, Rodriguez-Martinez CE.Principal findings of systematic reviews for chronic treatmentin childhood asthma. J Asthma. 2015 May;52(4):407-16. 11.Placebo versus Budesonid for chronic asthma in children andadults review. Cochrane Database Syst. Rev. 2008. 12.Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Flu-ticasone versus placebo for chronic asthma in adults and child-ren. Cochrane Database Syst. Rev. 2008. 13.Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ,Chris-todoulopoulos P,Hamid Q. Effect of HFA-flunisolide on pe-ripheral lung inflammation in asthma. J Allergy Clin Immu-nol. 2003 Jul;112(1):58-63. 14.Ohbayashi H. One-year evaluation of the preventative effectof hydrofluoroalkane-beclomethasone dipropionate on eosi-nophilic inflammation of asthmatic peripheral airways. Res-piration. 2007;74(2):146-53. 15.Dahl R. Ciclesonide for the treatment of asthma. Ther. ClinRisk Manag. 2006 Mar; 2(1) 25-38. 16.Hoshino M. Comparison of effectiveness in ciclesonide andfluticasone propionate on small airway function in mild asth-ma. Allergol Int. 2010 Mar;59(1):59-66. 17.Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H,Jinnai M, Otsuka K, Oguma T, Takeda T, Ito I, Matsumoto H,Hirai T, Chin K, Mishima M. Effect of inhaled corticostero-ids on small airways in asthma: investigation using impulseoscillometry. Pulm Pharmacol Ther. 2009 Aug;22(4):326-32. 18.Pedersen S1, Potter P, Dachev S, Bosheva M, Kaczmarek J,Springer E, Dunkel J, Engelstätter R. Efficacy and safety of threeciclesonide doses vs placebo in children with asthma: the RA-INBOW study. Respir Med. 2010 Nov;104(11):1618-28. 19.Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M,Postma DS. Ciclesonide improves measures of small airway in-volvement in asthma. Eur Respir J. 2008 Jun;31(6):1213-20. 20.Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S,Lindh A, Petermann W, Aubier M, Schwabe G, Bengts-son T; RELIEF Study investigators. Formoterol as relief me-dication in asthma: a worldwide safety and effectiveness tri-al. Eur Respir J. 2003 Nov;22(5):787-94. 21.Miraglia del Giudice M, Matera MG, Capristo C, Conte M, San-taniello F,Chinellato I, Leonardi S, Miraglia del Giudice MC,Perrone L. LABAs in asthmatic children: highlights and newinside. Pulm Pharmacol Ther. 2013 Oct;26(5):540-3. 22.Harmanci K. Montelukast: its role in the treatment of child-hood asthma. Ther Clin Risk Manag. 2007 Oct;3(5):885-92. 23.Chauhan BF, Ducharme FM. Anti-leukotriene agents compa-red to inhaled corticosteroids in the management of recurrentand/or chronic asthma in adults and children. Cochrane Da-tabase Syst Rev. 2012. 24.Overbeek SE, O'Sullivan S, Leman K, Mulder PG, Hoogste-den HC, Prins JB. Effect of montelukast compared with inha-led fluticasone on airway inflammation. Clin Exp Allergy. 2004Sep;34(9):1388-94. 25.Massingham K, Fox S, Smaldone A. Asthma therapy in pedi-atric patients: a systematic review of treatment with monte-lukast versus inhaled corticosteroids. JPediatr Health Care.2014 Jan-Feb;28(1):51-62. 26.Pedersen SE, Hurd SS, Lemanske RF Jr, Becker A, Zar HJ,Sly PD, Soto-Quiroz M, Wong G, Bateman ED; Global Ini-tiative for Asthma. Global strategy for the diagnosis and ma-nagement of asthma in children 5 years and younger. Pedi-atr Pulmonol. 2011 Jan;46(1):1-17. 27.Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Oma-lizumab for asthma in adults and children. Cochrane Data-base Syst Rev. 2014. 28.Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K,Woolacott N. Omalizumab for the treatment of severe persis-tent allergic asthma in children aged 6-11 years: a NICE sin-gle technology appraisal. Pharmacoeconomics. 2012 Nov1;30(11):991-1004. 29.Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.Anti-IgE for chronic asthma in adults and children. Cochra-ne Database Syst Rev. 2006.
Year 2017,
Volume: 9 Issue: 2, 32 - 38, 15.03.2017
Abstract
Öz
Astım, dünya nüfusunun %1-18’ini etkileyen kronik inflamatuvar bir hava yolu hastalığıdır. Hırıltı, nefes darlığı, göğüste daralma hissi ve/veya öksürük ve değişken klinik ile gelen ekspiratuvar hava yolu kısıtlılığı ile karakterizedir. Semptomlarve hava yolu kısıtlılığı kendiliğinden veya medikal tedavi ile düzelebilmektedir. Derlememizde astımın literatür eşliğinde güncellenmiş tedavisini özetlemekteyiz.
References
- Kaynaklar 1.Global strategy for asthma management and prevention. GINAreport 2016. http://www.ginasthma.org/2.Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med2004;10:44-50. 3.Anderson GP. Endotyping asthma: new insights into key pat-hogenic mechanisms in a complex, heterogeneous disease. Lan-cet 2008;372:1107-19. 4.British guideline on the Management of Asthma2014.https://www.brit-thoracic.org.uk/ 5.Archibald MM, Scott SD. The information needs of North Ame-rican parents of children with asthma: a state-of-the-sciencereview of the literature. J Pediatr Health Care. 2014 Jan-Feb;28(1):5-13.e2 6.Asthma Action Plan. Asthma Foundation NSW 2012. Retrie-ved from http://www.asthmafoundation.org.au/asthma acti-onplan.aspx 7.Gotzsche PC, Johansen HK. House dust mite control measu-res for asthma. Cochrane Database Syst Rev. 2008. 8.Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med1995;333(8):499-506. 9.McDonald N, Bara A, McKean MC. Anticholinergic therapyfor chronic asthma in children over two years of age. Coch-rane Database Syst Rev 2003;(3). 10.Castro-Rodriguez JA, Rodrigo GJ, Rodriguez-Martinez CE.Principal findings of systematic reviews for chronic treatmentin childhood asthma. J Asthma. 2015 May;52(4):407-16. 11.Placebo versus Budesonid for chronic asthma in children andadults review. Cochrane Database Syst. Rev. 2008. 12.Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Flu-ticasone versus placebo for chronic asthma in adults and child-ren. Cochrane Database Syst. Rev. 2008. 13.Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ,Chris-todoulopoulos P,Hamid Q. Effect of HFA-flunisolide on pe-ripheral lung inflammation in asthma. J Allergy Clin Immu-nol. 2003 Jul;112(1):58-63. 14.Ohbayashi H. One-year evaluation of the preventative effectof hydrofluoroalkane-beclomethasone dipropionate on eosi-nophilic inflammation of asthmatic peripheral airways. Res-piration. 2007;74(2):146-53. 15.Dahl R. Ciclesonide for the treatment of asthma. Ther. ClinRisk Manag. 2006 Mar; 2(1) 25-38. 16.Hoshino M. Comparison of effectiveness in ciclesonide andfluticasone propionate on small airway function in mild asth-ma. Allergol Int. 2010 Mar;59(1):59-66. 17.Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H,Jinnai M, Otsuka K, Oguma T, Takeda T, Ito I, Matsumoto H,Hirai T, Chin K, Mishima M. Effect of inhaled corticostero-ids on small airways in asthma: investigation using impulseoscillometry. Pulm Pharmacol Ther. 2009 Aug;22(4):326-32. 18.Pedersen S1, Potter P, Dachev S, Bosheva M, Kaczmarek J,Springer E, Dunkel J, Engelstätter R. Efficacy and safety of threeciclesonide doses vs placebo in children with asthma: the RA-INBOW study. Respir Med. 2010 Nov;104(11):1618-28. 19.Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M,Postma DS. Ciclesonide improves measures of small airway in-volvement in asthma. Eur Respir J. 2008 Jun;31(6):1213-20. 20.Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S,Lindh A, Petermann W, Aubier M, Schwabe G, Bengts-son T; RELIEF Study investigators. Formoterol as relief me-dication in asthma: a worldwide safety and effectiveness tri-al. Eur Respir J. 2003 Nov;22(5):787-94. 21.Miraglia del Giudice M, Matera MG, Capristo C, Conte M, San-taniello F,Chinellato I, Leonardi S, Miraglia del Giudice MC,Perrone L. LABAs in asthmatic children: highlights and newinside. Pulm Pharmacol Ther. 2013 Oct;26(5):540-3. 22.Harmanci K. Montelukast: its role in the treatment of child-hood asthma. Ther Clin Risk Manag. 2007 Oct;3(5):885-92. 23.Chauhan BF, Ducharme FM. Anti-leukotriene agents compa-red to inhaled corticosteroids in the management of recurrentand/or chronic asthma in adults and children. Cochrane Da-tabase Syst Rev. 2012. 24.Overbeek SE, O'Sullivan S, Leman K, Mulder PG, Hoogste-den HC, Prins JB. Effect of montelukast compared with inha-led fluticasone on airway inflammation. Clin Exp Allergy. 2004Sep;34(9):1388-94. 25.Massingham K, Fox S, Smaldone A. Asthma therapy in pedi-atric patients: a systematic review of treatment with monte-lukast versus inhaled corticosteroids. JPediatr Health Care.2014 Jan-Feb;28(1):51-62. 26.Pedersen SE, Hurd SS, Lemanske RF Jr, Becker A, Zar HJ,Sly PD, Soto-Quiroz M, Wong G, Bateman ED; Global Ini-tiative for Asthma. Global strategy for the diagnosis and ma-nagement of asthma in children 5 years and younger. Pedi-atr Pulmonol. 2011 Jan;46(1):1-17. 27.Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Oma-lizumab for asthma in adults and children. Cochrane Data-base Syst Rev. 2014. 28.Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K,Woolacott N. Omalizumab for the treatment of severe persis-tent allergic asthma in children aged 6-11 years: a NICE sin-gle technology appraisal. Pharmacoeconomics. 2012 Nov1;30(11):991-1004. 29.Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.Anti-IgE for chronic asthma in adults and children. Cochra-ne Database Syst Rev. 2006.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | makale |
| Authors | |
| Publication Date | March 15, 2017 |
| Published in Issue | Year 2017 Volume: 9 Issue: 2 |
